Vikas Goyal took the unusual step of leaving his investor role at SR One to join portfolio company Pandion Therapeutics full-time as an executive, where he led the company through partnerships, IPO, and ultimately Merck's $1.85B acquisition before returning to venture capital. He was an early institutional backer of computational drug discovery over a decade ago at Nimbus Therapeutics and argues that the real bottleneck for AI in drug development is high-quality experimental data rather than algorithms.